CAS 127910-31-0|CGP 37849
| Common Name | CGP 37849 | ||
|---|---|---|---|
| CAS Number | 127910-31-0 | Molecular Weight | 209.13700 |
| Density | 1.506 g/cm3 | Boiling Point | 523.1ºC at 760 mmHg |
| Molecular Formula | C6H12NO5P | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 270.2ºC |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid |
|---|---|
| Synonym | More Synonyms |
CGP 37849 BiologicalActivity
| Description | CGP 37849 is a potent, competitive and orally active N-methyl-D-aspartate (NMDA) receptor antagonist. CGP 37849 is an anticonvulsant in rodents and has antidepressant and anxiolytic-like effects[1]. |
|---|---|
| Related Catalog | Signaling Pathways >>Neuronal Signaling >>iGluRSignaling Pathways >>Membrane Transporter/Ion Channel >>iGluR |
| In Vitro | In the hippocampal slice in vitro, CGP 37849 selectively and reversibly antagonizes NMDA-evoked increases in CA1 pyramidal cell firing rate. In slices bathed in medium containing low Mg2+ levels, concentrations of CGP 37849 up to 10 μM suppresses burst firing evoked in CA1 neurones by stimulation of Schaffer collateral-commissural fibres without affecting the magnitude of the initial population spike[1]. |
| In Vivo | CGP 37849 potently (Ki of 220 nM) and competitively inhibits NMDA-sensitive l-[3H]-glutamate binding to postsynaptic density (PSD) fractins from rat brain. CGP 37849 inhibits the binding of the selective NMDA receptor antagonist, [3H]-(±)-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP), with a Ki of 35 nM[1]. In vivo, oral administration to rats of CGP 37849 selectively blocks firing in hippocampal neurones induced by ionophoretically-applied NMDA, without affecting the responses to quisqualate or kainate[1]. Oral administration to mice of CGP 37849 suppresses maximal electroshock-induced seizures in mice with an ED50 of 21 mg/kg[1]. |
| References | [1]. Fagg GE, et al. CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity. Br J Pharmacol. 1990 Apr;99(4):791-7. [2]. Schmutz M, et al. The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):61-6. [3]. Papp M, et al. Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol. 1994 Sep 22;263(1-2):1-7. [4]. Przegaliński E, et al. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology. 2000 Jul 24;39(10):1858-64. |
Chemical & Physical Properties
| Density | 1.506 g/cm3 |
|---|---|
| Boiling Point | 523.1ºC at 760 mmHg |
| Molecular Formula | C6H12NO5P |
| Molecular Weight | 209.13700 |
| Flash Point | 270.2ºC |
| Exact Mass | 209.04500 |
| PSA | 130.66000 |
| LogP | 0.22260 |
| InChIKey | BDYHNCZIGYIOGJ-DUXPYHPUSA-N |
| SMILES | CC(=CC(N)C(=O)O)CP(=O)(O)O |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P261-P305 + P351 + P338 |
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |
Articles26
More Articles| Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. Kidney Int. 63(5) , 1764-75, (2003) Renal failure has been viewed as a state of cellular calcium toxicity due to the retention of small fast-acting molecules. We have tested this hypothesis and identified potentially neuroexcitatory com... | |
| GSA: behavioral, histological, electrophysiological and neurochemical effects. Physiol. Behav. 84(2) , 251-64, (2005) Renal insufficient patients suffer from a variety of complications as direct and indirect consequence of accumulation of retention solutes. Guanidinosuccinic acid (GSA) is an important probable uremic... | |
| Competitive NMDA receptor antagonists and agonists: effects on spontaneous alternation in mice exposed to cerebral oligemia. Pol. J. Pharmacol. 56(1) , 59-66, (2004) The purpose of the present study was to investigate the effects of competitive NMDA receptor antagonists,D,L-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 37849) and its ethyl ester (CGP 3955... |
Synonyms
| Proglumide sodium salt |
| E-2-amino-4-methyl-5-phosphono-3-pentenoic acid |
| dl-2-amino-4-methyl-5-phosphono-3-*pentenoic acid |
